Experts’ Advice for the week of 2 April to 8 April, 2018

By | 3rd April 2018

Experts’ Advice for the Week

BUY | HOLD | SELL     What to do?

What can you Buy or Sell? Top 7 stocks from different brokerage houses with their comments.


Indian Bank:

Research House: Reliance Securities
Advice: BUY
Market Price Rs.: 299
1 Year Target Price Rs.: 445
Potential Upside: 45%
Maintain BUY.
Indian Bank continues to be the best manages Public sector bank. Its stressed loan cycle is ending and indicates a sharp moderation in credit cost from 2018-19 onwards.


Persistent Systems:

Research House: Edelweiss Research
Advice: BUY
Market Price Rs.: 691
1 Year Target Price Rs.: 1014
Potential Upside: 47%
Maintain BUY.
The recent correction in the counter is a good entry point because the company is expected to recover its lost revenue over the next two quarters.


Container Corp:

Research House: Jefferies India
Advice: BUY
Market Price Rs.: 1244
1 Year Target Price Rs.: 1750
Potential Upside: 41%
Retain BUY.
Railways continue to gain market share from roads and further re-rating is possible for Concor. Expect 30% earnings CAGR and strong cash flows between 2016-17 and 2019-20.


Aditya Birla Capital:

Research House: Axis Capital
Advice: BUY
Market Price Rs.: 146
1 Year Target Price Rs.: 195
Potential Upside: 34%
Initiate BUY.
NBFC, mutual fund, insurance, and housing finance will be Aditya Birla Capital’s key growth drivers for the next three years.

You may like this: Get your investment process back on track in a new financial year


IRB Infra:

Research House: Yes Securities
Market Price Rs.: 223
1 Year Target Price Rs.: 295
Potential Upside: 32%
Initiate Accumulate.
Foray into hybrid annuity model with assured cash flows and the upcoming toll-operate-transfer opportunity should provide its next leg of growth and lead to re-rating.


Engineers India:

Research House: Kotak Securities
Advice: BUY
Market Price Rs.: 158
1 Year Target Price Rs.: 204
Potential Upside: 29%
Retain BUY.

The recent correction in this counter is driven by weak order inflows in the current quarter. The long term prospects of the company are positive.


Cadila Healthcare:

Research House: Elara Capital
Advice: BUY
Market Price Rs.: 379
1 Year Target Price Rs.: 468
Potential Upside: 24%
Upgrade to BUY.

Strong US sales during the first nine months of 2017-18. Expect this momentum to continue into 2018-19, led by high value and niche launches such as gToprol.

You might like this: Book Review: Brightest Investment Minds

Our Blog website:

Follow us on Facebook:

Follow us on YouTube:


My descriptions, videos, presentations are only for educational and information purposes and under no circumstances should be used for making investment decisions. I cannot guarantee the accuracy of any information provided.
The stocks picks are based on my own research and personal views and sometimes are from newspapers, tv channel program, magazines, etc. No part of compensation is or will be directly or indirectly related to the views and recommendations of this research. I have not served as an officer director or employee of the company and have not been engaged in the market – making the activity of the company covered in the research report. Consult qualified financial advisor before making any investment decision.

Leave a Reply

Your email address will not be published. Required fields are marked *